|
1
|
International Agency for Research on
Cancer (IARC), . GLOBOCAN 2008: Cancer Incidence and Mortality
Worldwide. IARC; Lyon: 2010, https://www.iarc.fr/en/media-centre/iarcnews/2010/globocan2008.phpMay
1–2010
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fang Y, Shang QL, Liu JY, Li D, Xu WZ,
Teng X, Zhao HW, Fu LJ, Zhang FM and Gu HX: Prevalence of occult
hepatitis B virus infection among hepatopathy patients and health
people in China. J Infect. 58:383–388. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Al-Rawashdeh FY, Scriven P, Cameron IC,
Vergani PV and Wyld L: Unfolded protein response activation
contributes to chemoresistance in hepatocellular carcinoma. Eur J
Gastroenterol Hepatol. 22:1099–1105. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee CH: Reversing agents for ATP-binding
cassette drug transporters. Methods Mol Biol. 596:325–340. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Anders M, Christian C, McMahon M,
McCormick F and Korn WM: Inhibition of the Raf/MEK/ERK pathway
up-regulates expression of the coxsackievirus and adenovirus
receptor in cancer cells. Cancer Res. 63:2088–2095. 2003.PubMed/NCBI
|
|
8
|
Viala E and Pouysségur J: Regulation of
tumor cell motility by ERK mitogen-activated protein kinases. Ann N
Y Acad Sci. 1030:208–218. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wilkinson MG and Millar JB: Control of the
eukaryotic cell cycle by MAP kinase signaling pathways. FASEB J.
14:2147–2157. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Johnson GL and Lapadat R:
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and
p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shen H, Xu W, Luo W, Zhou L, Yong W, Chen
F, Wu C, Chen Q and Han X: Upregulation of mdr1 gene is related to
activation of the MARK/ERK signal transduction pathway and YB-1
nuclear translocation in B-cell lymphoma. Exp Hematol. 39:558–569.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abrams SL, Steelman LS, Shelton JG, Wong
EW, Chappell WH, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra
M, et al: The Raf/MEK/ERK pathway can govern drug resistance,
apoptosis and sensitivity to targeted therapy. Cell Cycle.
9:1781–1791. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Katayama K, Yoshioka S, Tsukahara S,
Mitsuhashi J and Sugimoto Y: Inhibition of the mitogen-activated
protein kinase pathway results in the down-regulation of
P-glycoprotein. Mol Cancer Ther. 6:2092–2102. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Berger W, Setinek U, Hollaus P, Zidek T,
Steiner E, Elbling L, Cantonati H, Attems J, Gsur A and Micksche M:
Multidrug resistance markers P-glycoprotein, multidrug resistance
protein1, and lung resistance protein in non-small cell lung
cancer: Prognostic implications. J Cancer Res Clin Oncol.
131:355–363. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang J, Zhang J, Zhang L, Zhao L, Fan S,
Yang Z, Gao F, Kong Y, Xiao GG and Wang Q: Expression of P-gp, MRP,
LRP, GST-π and TopoIIα and intrinsic resistance in human lung
cancer cell lines. Oncol Rep. 26:1081–1089. 2011.PubMed/NCBI
|
|
16
|
Tivnan A, Zakaria Z, O'Leary C, Kögel D,
Pokorny JL, Sarkaria JN and Prehn JH: Inhibition of multidrug
resistance protein1 (MRP1) improves chemotherapy drug response in
primary and recurrent glioblastoma multiforme. Front Neurosci.
9:2182015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stavrovskaya AA: Cellular mechanisms of
multidrug resistance of tumor cells. Biochemistry (Mosc).
65:95–106. 2000.PubMed/NCBI
|
|
18
|
Snow K and Judd W: Characterisation of
Adriamycin- and amsacrine-resistant human leukaemic T cell lines.
Br J Cancer. 63:17–28. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chaudhary PM and Roninson IB: Induction of
multidrug resistance in human cells by transient exposure to
different chemotherapeutic drugs. J Natl Cancer Inst. 85:632–639.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang XK and Fu LW: Interaction of tyrosine
kinase inhibitors with the MDR-related ABC transporter proteins.
Curr Drug Metab. 11:618–628. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu Y, Bally M, Dragowska WH and Mayer L:
Inhibition of mitogen-activated protein kinase/extracellular
signal-regulated kinase enhances chemotherapeutic effects on H460
human non-small cell lung cancer cells through activation of
apoptosis. Mol Cancer Ther. 2:641–649. 2003.PubMed/NCBI
|
|
22
|
Eum KH, Ahn SK, Kang H and Lee M:
Differential inhibitory effects of two Raf-targeting drugs,
sorafenib and PLX4720, on the growth of multidrug-resistant cells.
Mol Cell Biochem. 372:65–74. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee JT Jr, Steelman LS and McCubrey JA:
Phosphatidylinositol 3′-kinase activation leads to multidrug
resistance protein-1 expression and subsequent chemoresistance in
advanced prostate cancer cell. Cancer Res. 64:8397–8404. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tazzari PL, Cappellini A, Ricci F,
Evangelisti C, Papa V, Grafone T, Martinelli G, Conte R, Cocco L,
McCubrey JA and Martelli AM: Multidrug resistance-associated
protein 1 expression is under the control of the phosphoinositide 3
kinase/Akt signal transduction network in human acute myelogenous
leukemia blasts. Leukemia. 21:427–438. 2007. View Article : Google Scholar : PubMed/NCBI
|
